Prerpints.org logo

Submitted:

03 February 2025

Posted:

04 February 2025

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Background: Patent ductus arteriosus (PDA) in preterm infants presents a significant challenge in neonatal care, marked by ongoing debates about its definition, diagnosis, treatment options, and effects on patient outcomes. Plasma biomarkers assess mediators involved in PDA closure and hemodynamic responses, assisting in identifying newborns at higher risk of developing potentially serious neonatal conditions. The purpose of this review was to investigate the relationship between PDA and various plasma biomarkers used to evaluate and diagnose ductal patency during perinatal life, as outlined in the relevant literature. Methods: We conducted an electronic search of the National Library of Medicine (MEDLINE)/PubMed and Web of Science for relevant studies published up to December 2024, including prospective, retrospective, cohort, and cross-sectional studies, as well as reviews and meta-analyses. The keywords used in the search included “preterm infant,” “persistent ductus arteriosus,” “PDA,” “neonatal biomarkers,” “cardiac biomarkers,” and “vasoactive biomarkers.” Results: Out of the 813 identified articles, 85 were included in our review of cardiac biomarkers: Natriuretic peptides (NPs), Cardiac troponin T (cTnT), vasoactive biomarkers (Mid-regional pro-adrenomedullin (MR-proADM), Endothelin-1 (ET-1), Copeptin, and Isoprostanes (IPs)), and inflammatory biomarkers (Interleukin-6 (IL-6), IL-8, IL-10, Growth Differentiation Factor 15 (GDF-15), Monocyte Chemoattractant Protein-1 (MCP-1/CCL2), Macrophage Inflammatory Protein-1α (MIP-1α/CCL3)) in relation to PDA. Conclusions: Even if research shows a strong correlation between specific biomarkers and echocardiographic parameters in patients with PDA, clinical judgment must take these evaluations into account, particularly when determining whether to treat a PDA. Future research should focus on investigating new biomarkers associated with the underlying mechanisms of perinatal ductus arteriosus dynamics in preterm infants.
Keywords: 
PDA
;  
preterm infant
;  
Natriuretic peptides
;  
Cardiac troponin T
;  
MR-proADM
;  
Endothelin-1
;  
Isoprostanes
;  
inflammatory biomarkers
Subject: 
Medicine and Pharmacology  -   Pediatrics, Perinatology and Child Health

1. Introduction

Patent ductus arteriosus (PDA) in preterm infants presents a significant challenge in neonatal care, marked by ongoing debates about its definition, diagnosis, treatment options, and effects on patient outcomes [1]. The ductus arteriosus (DA) is a fetal structure that connects the main pulmonary artery to the proximal descending aorta, allowing blood to bypass the nonfunctional fetal lung [2,3]. The patency of the fetal DA is essential for fetal survival and is primarily maintained by vasodilatory mechanisms. Relative intrauterine hypoxia [3], along with the activation of Prostaglandin E2 (PGE2) through the EP4 receptor in DA endothelial cells [4,5], plays a crucial role in maintaining fetal ductal permeability. Mediators such as adenosine and atrial natriuretic peptides contribute by upregulating cAMP and cGMP signaling pathways, respectively [6]. The production of nitric oxide (NO) in the endothelium of both the lumen and the vasa vasorum, combined with the formation of carbon monoxide (CO), supports the maintenance of fetal ductal patency. Carbon monoxide inhibits the oxygen-sensing cytochrome P450 and reduces the synthesis of endothelin-1 (ET-1), a potent endogenous vasoconstrictor [7].
Conversely, the initiation of breathing at birth increases blood oxygen levels and decreases PGE2 levels after placental removal, leading to the spontaneous closure of the ductus arteriosus (DA) in full-term infants within 24 to 36 hours [8]. Increased oxygen levels enhance oxidative phosphorylation, inhibit potassium channels, and promote Ca2+ influx, leading to vasoconstriction of DA [9]. Oxygen-induced vasoconstriction is also linked to increased ET-1 synthesis and the production of reactive oxygen species (ROS), which drive the formation of peroxidation products (Isoprostanes) in response to oxidative stress [8,10,11]. The permanent anatomical closure of the DA involves a complex remodeling process until it transforms into the ligamentum arteriosum [5,12].
Timing issues related to the closure of the DA include intrauterine obstruction and prolonged patency. Intrauterine closure of DA is a rare condition that can have grave consequences. Physiologically, excessive blood flow in the fetal pulmonary circulation can lead to severe pulmonary hypertension, right heart failure, fetal hydrops, and even intrauterine death in extreme cases [13,14]. The premature closure of DA is most linked to maternal ingestion of corticosteroids or nonsteroidal anti-inflammatory drugs or low levels of circulating endogenous prostaglandins. Additionally, a maternal diet high in nutrients that contain prostaglandin synthase inhibitors, such as green tea, dark chocolate, or grape juice, may also contribute to the closure of the DA [13,15,16].
Failure of DA closure beyond 48-72 hours after birth leads to patent/persistent ductus arteriosus (PDA), affecting 70% of infants born with a gestational age (GA) of less than 28 weeks [17,18]. Patent ductus arteriosus can lead to hemodynamic issues, including pulmonary overcirculation, systemic hypoperfusion, and decreased perfusion in organs such as the bowel, kidneys, brain, and heart due to the ductal steal phenomenon. These changes can lead to severe conditions, including pulmonary hemorrhage, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), and acute kidney injury [19,20].
The definition of a hemodynamically significant patent ductus arteriosus (hsPDA) is not standardized and is based on clinical severity scores and ultrasound criteria. Specifically, it includes a ductus arteriosus size greater than 1.5 mm, a left atrial-to-aortic diameter (LA/Ao) ratio exceeding 1.4, and retrograde or absent diastolic flow in the descending aorta, celiac trunk/superior mesenteric artery, or cerebral arteries [19,21]. The term hsPDA typically refers to a symptomatic PDA that leads to hemodynamic instability.
Echocardiography is the gold standard for assessing PDA, but it is not always easily accessible, particularly in resource-limited settings. In contrast, plasma biomarkers—either used alone or combined with echocardiography and clinical signs—are more accessible. These biomarkers assess mediators involved in PDA closure and hemodynamic responses, assisting in identifying newborns at higher risk of developing potentially serious neonatal conditions [22].
Early identification of newborns at risk for delayed closure of the DA is crucial for effective monitoring and treatment, helping to prevent complications related to this condition. The purpose of this review was to investigate the relationship between PDA and various plasma biomarkers used to evaluate and diagnose ductal patency during perinatal life, as outlined in the relevant literature.

2. Materials and Methods

This narrative review of the literature synthesizes research on biomarker monitoring in preterm infants with PDA. The study includes the most relevant articles concerning enrolled preterm infants and plasma measurements conducted. We searched the National Library of Medicine (MEDLINE)/PubMed and Web of Science for pertinent published studies published up to January 2025, encompassing prospective, retrospective, cohort, cross-sectional studies, reviews, and meta-analyses. The keywords used in the search were “preterm infant,” “persistent ductus arteriosus,” “PDA,” “neonatal biomarkers,” “cardiac biomarkers,” and “vasoactive biomarkers.” The “snowball literature searching method” was used to find additional relevant sources from the reference lists of chosen articles. Out of the 813 identified articles, 728 were excluded because they did not relate to the keyword “biomarkers.” Ultimately, 85 articles were included in our review.

3. Results

Each study used a diverse set of biomarkers for monitoring, with variations in measurement timing and biological sample types. Most assessments focused on blood samples, while urinary assessments were less common.

3.1. Cardiovascular Markers

3.1.1. Natriuretic Peptides (NPs)

Natriuretic peptides are a family of hormones that directly influence the cardiovascular system, affecting cellular proliferation, angiogenesis, apoptosis, fibrosis, and inflammation [23].
  • Atrial natriuretic peptide (ANP)
The atria secrete atrial natriuretic peptide (ANP) in response to increased intracavitary pressure, which typically occurs during volume overload. The physiological effects of ANP primarily occur in the kidneys by dilating the afferent arterioles and constricting the efferent arterioles of the renal tubules, which increases the glomerular filtration rate and promotes diuresis. Additionally, ANP inhibits renin secretion and decreases sodium and water reabsorption in the renal tubules, resulting in lower systemic blood pressure [24]. Immediately after birth, levels of ANP are significantly higher in newborns compared to older children, with a mean concentration of 227 pg/ml versus 47 pg/ml. This elevation may be attributed to the immature myocardium’s inability to manage the increased left and right ventricular afterload. In preterm infants with hsPDA, even higher ANP levels are observed, with a median of 1240 pg/ml. Lower plasma ANP levels may indicate successful therapeutic closure of PDA [25,26]. These levels usually normalize within a few months [25].
  • Brain natriuretic peptide (BNP)
Ventricular cardiomyocytes release brain natriuretic peptide (BNP) in response to increased wall stress. This peptide helps in regulating blood pressure by promoting vasodilation, diuresis, and sodium excretion, thereby improving cardiac function [27]. Brain natriuretic peptide is the biologically active compound that results from the cleavage at a ratio of 1:1 of the inactive precursor pro-BNP into BNP and the inactive amino-terminal fragment NT-proBNP [28,29]. BNP levels rise immediately after birth, then significantly decrease during the first week of life, eventually reaching adult-specific levels at about one month of age. [30,31]. Both BNP and pro-BNP have been established as early, non-specific biomarkers for hemodynamic myocardial stress, regardless of the underlying pathology, and they exhibit comparable diagnostic performance. However, it is considered that NT-proBNP is a superior marker for myocardial wall stress due to its longer half-life (60-120 minutes) compared to BNP (20 minutes). Serum values of NT-proBNP are approximately six times higher than those of BNP for the same reason [29,32,33].
There is evidence that BNP and NT-proBNP serum levels are influenced by conditions related to prematurity, such as respiratory distress syndrome (RDS), pulmonary hypertension and BPD [34,35,36], ROP [37,38], sepsis [35,39], and particularly by hsPDA [40,41,42,43,44,45,46,47,48,49,50]. Cucerea et al. observed that surfactant administration was significantly associated (p=0.024) with increased median NT-proBNP levels in a study of 88 preterm infants born at or below 32 weeks of gestational age. The surfactant group had a median level of 12962.6 (7333.7–25934.8) pg/mL, while the non-surfactant group had a median level of 9621.6 (3463.2–17381.8) pg/mL at 24 hours of life. Patients in the surfactant group also experienced decreased pre- and post-ductal diastolic pressure, changes that may be related to DA persistence [19].
Various authors have investigated the diagnostic accuracy of BNP and NT-proBNP in relation to hsPDA. The results varied significantly due to differences in commercial testing kit characteristics, reference thresholds, study methodology, definition of PDA, and the gestational and chronological ages of the patients involved. Thus, the cutoff values for diagnosing hsPDA were established according to these conditions [40,41,42,43,44,45,46,47,48,49,50]. Table 1 and Table 2 represent the main results of studies regarding the association between plasma BNP and NT-proBNP levels and PDA in preterm infants.
Shin et al. proposed serial BNP measurements during the management of hsPDA as a tool for predicting and diagnosing symptomatic PDA in preterm infants. This approach also serves as a guide for early constrictive responses to cyclooxygenase inhibitors (ibuprofen). They estimated that a BNP level lower than 600 pg/ml would be used for individualized pharmacological treatment (one or two doses) to prevent unnecessary cyclooxygenase inhibitor doses [51].
König et al. conducted a prospective study involving preterm infants with a gestational age of less than 32 weeks, examining the specificity of two distinct markers. BNP and NT-proBNP serum levels were measured prior to the echocardiographic examination performed in the first four days of life. Data from 58 enrolled neonates demonstrated that both BNP and NT-proBNP were closely correlated with the size of PDA, making them equally practical for assessing PDA in preterm infants [42].
A review of 34 studies—13 on BNP with 768 infants and 21 on NT-proBNP involving 1,459 infants—assessed the accuracy of both biomarkers in diagnosing hsPDA in preterm infants. Despite low-certainty evidence and moderate accuracy, these markers can be considered for initiating and monitoring treatment if validated locally alongside clinical and echocardiographic criteria, even without universal agreements on their use. Testing infants under 30 weeks of gestational age in the first 1 to 3 days of life improves diagnostic accuracy [61,62].

3.1.2. Cardiac Troponin T (cT)

Cardiac troponins (cT) are proteins in the troponin-tropomyosin complex of the myocardium. They facilitate the interaction between actin and myosin in cardiac muscle. They include troponins C (cTnC, calcium-binding), I (cTnI, inhibitory), and T (cTnT, tropomyosin binding), along with tropomyosin [63,64]. Under normal physiological conditions, cTnT can be detected in plasma at very low levels. Consequently, elevated levels are observed during myocardial injury, making them a specific biochemical marker (the gold standard) widely used in adults for acute coronary syndromes, myocardial infarction, acute heart failure, tachyarrhythmias, pulmonary embolism, and sepsis. Troponin levels are detectable in the blood 2 to 4 hours after injury, peaking at 12 hours and staying elevated for 7 to 10 days [65]. Low cTnT levels can occur in chronic cardiac (heart failure) and non-cardiac conditions (chemotherapy). The latest high-sensitivity cardiac troponin (hs-cTnT) assays can detect even minor myocardial injury in asymptomatic patients [66].
Limited reports exist on serum troponin levels in newborns, particularly in managing PDA. In a study of 158 full-term newborns, Karlén et al. found that hs-cTnT levels in cord blood [34 pg/mL (26–44)] were elevated compared to adult values and increased further during the first 2 to 5 days of life [92 pg/mL (54–158)]. A plausible reason is cardiac stress resulting from significant changes in the right ventricle, along with pulmonary and systemic vascular resistance during the transition to extrauterine life [64]. A study by Tarkowska et al. found that cTnT levels in newborns correlate with postmenstrual age rather than chronological age, and they are not influenced by sex, mode of delivery, or blood saturation [63].
Some studies have found elevated serum cTnT levels in neonates with respiratory distress [67,68] and perinatal asphyxia [69,70]. Few studies have explored the relationship between cTnT and PDA in preterm infants. Diastolic steal decreases coronary blood flow, causing potential ischemia and alterations in cTnT levels [57,71,72,73]. Table 3 represents the main results of studies regarding cTnT levels and PDA in preterm infants.
Study results vary based on the cTnT assay, methodology, and the gestational and postnatal ages of the infants involved. Most studies have demonstrated a correlation between serum cTnT levels, and the size of PDA as seen in echocardiographic examinations. This indicates that cTnT, combined with clinical evaluation and echocardiography, is a reliable diagnostic tool for PDA.

3.2. Vasoactive Biomarkers

3.2.1. Mid-Regional Pro-Adrenomedullin (MR-proADM)

Mid-regional pro-adrenomedullin (MR-proADM) is a biomarker that serves as a precursor to adrenomedullin (ADM), an unstable vasoactive peptide with a half-life of about 22 minutes, produced by vascular endothelial cells. Factors such as pro-inflammatory cytokines, bacterial endotoxin, hypervolemia, and hypoxia lead to an increase in this biomarker [76].
MR-proADM demonstrates better stability, allowing for accurate measurement. Due to its immunomodulatory, diuretic, bactericidal, and vasodilatory properties, it has clinical applications in cardiovascular disorders, sepsis, renal failure, tumor pathology, and other conditions involving vascular damage. It indicates the endothelial function, providing data on vascular bed reactivity and coagulation status [77]. Elevated levels of MR-proADM are associated with increased microvascular permeability and plasma leakage into the extracellular space. In patients experiencing septic shock, MR-proADM levels are elevated, leading to hypotension by affecting vascular tone.
MR-proADM is a more reliable marker than procalcitonin (PCT) or C-reactive protein (CRP) for assessing prognosis and mortality risk in patients with sepsis admitted to Intensive Care Units [78,79]. Fahmey et al. observed that septic newborn infants had significantly higher serum levels of MR-proADM, measuring 14.39 ± 0.75 nmol/L, compared to non-septic newborns, which had levels of 3.12 ± 0.23 nmol/L. The study identified a cutoff value for pro-ADM at 4.3 nmol/L, demonstrating a sensitivity of 93.3% and a specificity of 86.7% [80].
Birth weight and gestational age (GA) were inversely related to MR-proADM plasmatic levels in the venous umbilical cord (GA 24–31 weeks: 1.4 nmol/l; GA 32–36 weeks: 1.1 nmol/l; GA 37–41 weeks: 1.0 nmol/l) in a prospective study conducted by Admaty on 328 newborn infants. In very preterm infants, elevated MR-proADM plasma levels at 2 to 3 days of life were associated with diastolic run-off through a PDA [81]. Wu et al. reported significantly reduced plasma MR-proADM levels after transcatheter closure of PDA [82].

3.2.2. Endothelin-1 (ET-1)

Endothelin-1 is a potent endogenous peptide produced by endothelial cells that acts as both a vasoconstrictor and a bronchoconstrictor. It stimulates natriuresis and diuresis and exerts its effects through two distinct receptor subtypes, triggering pro-inflammatory pathways, increasing superoxide anion production, and stimulating the release of endogenous cytokines. There is a clear correlation between plasma endothelin-1 levels and mortality rates in patients with septic shock, like MR-proADM [83,84].
C-terminal proendothelin-1 (CT-proET-1) is the stable circulating precursor of the active ET-1 molecule. This acts through two G protein-coupled receptors, the endothelin A receptor (ETA) and the endothelin B receptor (ETB). Both receptors induce an increase in intracellular calcium levels. ETA receptors primarily mediate arterial vasoconstriction, while the effect on the venous system is mediated by ETB receptors [85].
Research links preterm birth and elevated ET-1 levels to chronic lung disease and pulmonary hypertension in infants [86,87,88]. CT-proET1 is also involved in enabling crucial circulatory adaptations during the transition from fetal to neonatal life.
Letzner [89] identified a correlation between CT-proET-1 levels in treated and untreated Patent Ductus Arteriosus (PDA), reporting values of 388 (272-723) pmol/L for treated PDA and 303 (152-422) pmol/L for untreated PDA, with a statistically significant p-value of 0.011. This finding highlights the potential of CT-proET-1 as a predictor for PDA intervention, particularly when considering the left atrium to aorta (LA/Ao) ratio. In contrast, Grass [90] and Sellmer [91] contended that CT-proET-1 is not a dependable biomarker for assessing the size of PDA or the LA: Ao ratio in very preterm neonates.

3.2.3. Copeptin

Copeptin is the carboxyl-terminal part of the arginine vasopressin (AVP) precursor, synthesized in the hypothalamus. AVP, known as the antidiuretic hormone, has peripheral functions like vasoconstriction, kidney water reabsorption, and central effects. Consequently, antidiuretic hormones are essential for energy homeostasis and dietary habits, making them potential targets in treating metabolic diseases [92].
Unlike peripheral arterioles, AVP decreases resistance in the pulmonary artery, triggering the release of nitric oxide (NO) from endothelial cells, which has a vasodilatory effect during the transition from placental to lung breathing [93].
Copeptin is a stable compound that serves as a biomarker for vasopressin synthesis and functions in conditions like diabetes mellitus, inappropriate antidiuretic hormone secretion, stroke, and various cardiovascular, renal, and pulmonary disorders [94].
Copeptin concentrations were determined by 3 days of life in 167 preterm infants in a study conducted by Benzing. The study found significantly higher levels of copeptin in hsPDA than in closed PDA [38 (8 –199) pmol/L vs. 18 (1–64) pmol/L; p= 0.001][95].
A recent study investigated the relationship between five biomarkers (MR-proADM, NT-proBNP, mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-endothelin-1 (CT-proET1), and copeptin in correlation with echocardiographic findings of PDA in 139 preterm infants with a GA of less than 32 weeks. On day three of life, levels of MRproADM, NT-proBNP, MR-proANP, and copeptin were higher in neonates with significant PDA compared to those without. MR-proADM levels were 20% higher in neonates with a significant PDA on days 3 and 6, and there was a correlation between MR-proud and the left atrium to aorta (LA: Ao) ratio [91].

3.2.4. Isoprostanes (IPs)

Reactive oxygen species (ROS) generated in response to oxidative stress can lead to the peroxidation of membrane arachidonic acid, significantly impacting cellular function. Isoprostanes (IsoPs—F2-Isoprostanes) are metabolites formed from peroxidation reactions and can be detected in plasma and urine. Hyperoxia, inflammation, and infection elevate IsoP production [96,97]. Newborns, particularly preterm infants, have higher plasma levels of F2-isoprostanes than healthy adults, primarily due to their limited antioxidant defenses [98]. F2-isoprostanes are established biomarkers of oxidative stress and are implicated in various significant perinatal disorders, including intrauterine growth restriction, hypoxic-ischemic encephalopathy, bronchopulmonary dysplasia, periventricular leukomalacia, and retinopathy [97,98,99,100]. During the neonatal period, F2-isoprostanes play a physiological role in regulating the patency of the ductus arteriosus, with effects that vary depending on gestational age for both term and preterm infants [101]. Isoprostanes can cause either constriction or dilation of the ductus arteriosus, depending on the balance between thromboxane A2 (TxA2) and EP4 receptors found in ductal endothelial cells. IsoPs cause DA constriction after oxygen exposure by activating the thromboxane A2 (TxA2) receptor, or they can induce vasodilation by activating the prostaglandin E2 receptor 4 (EP4) [97,101]. In preterm DA, the TxA2 receptor expression is low, resulting in reduced contractile capacity, while the EP4 receptor is highly expressed, which promotes dilation. As gestation progresses, TxA2 and its contractile effects become more prevalent [101].
Fifty-three preterm infants born at or before 32 weeks of gestation participated in Inayat’s study, which evaluated antioxidants and oxidative stress biomarkers related to PDA using blood and urine samples collected within 24 to 48 hours after birth. At 24 and 48 hours, plasma 8-isoprostane (8-isoPGF2α) levels were significantly lower in preterm infants who subsequently developed a hsPDA (6060.9±5302.5 pg/mL, p < 0.01) than in those who did not (13281.5 ± 9161.7 pg/mL). The urinary levels of 8-isoprostane were similar in both the hsPDA group and infants without PDA, showing no change in response to treatment within the hsPDA group. The authors considered that preterm infants exhibit low levels of plasma and urinary isoprostanes shortly after birth due to relative hypoxia, suggesting that low 8-isoprostane could serve as a biomarker for hsPDA [102].
Coviello et al. studied the correlation between urinary isoprostane (IsoP) levels and hsPDA in sixty preterm infants (GA 23 to 34 weeks) diagnosed with RDS. The results indicated significantly higher IsoPs levels in infants with ibuprofen-treated hsPDA and who required surgical closure compared to those without PDA on the second day of life [2700.0 (1205.7–6688.0), 5028.7 (1233.0–17770.0)] vs. 969.9 (541.0–1470.6) ng/mg of creatinine; p < 0.01]. On the 10th day of life, urinary IsoPs levels were comparable in infants with and without hsPDA. The authors revealed a strong predictive ability of urinary IPos levels on the second day of life regarding the risk of developing hsPDA (AUC 0.78; 95% CI 0.65–0.71, p < 0.0001). They identified a cutoff level of 1627 ng/mg of creatinine, which predicts hsPDA with an 82% sensitivity and a 73% specificity [103].

3.3. Inflammatory Biomarkers

Pro-inflammatory conditions are known to delay the postpartum closure of the ductus arteriosus. Prenatal and postnatal inflammation significantly contribute to PDA, causing increased vascular tone and delayed closure. Chorioamnionitis triggers vascular remodeling via pro-inflammatory cytokines like interleukin-1 and TNF-alpha (tumor necrosis factor), resulting in PDA and contributing to persistent pulmonary hypertension in newborns. Elevated levels of interleukins (IL-6, IL-8, and IL-12) are seen in lung diseases and vascular remodeling. Using antenatal steroids and anti-inflammatory medications to treat chorioamnionitis lowers the risk and severity of PDA [104].
The ambiguity between inflammatory and infectious processes has complicated accurate assessments in studies. The evaluated biomarkers were not specific enough to identify PDA, as they could be elevated in various other conditions, especially within the same age group.

3.3.1. Interleukin-6 (IL-6)

Interleukin-6 (IL-6) is a cytokine that plays a key role in regulating the immune response and acute-phase reactions. IL-6 promotes the increase of IgM, IgG, and IgA and stimulates T helper cell proliferation during inflammation or infection. Although IL-6 is a promising biomarker for diagnosing certain conditions, its effectiveness can vary based on the context. There is significant individual variation in IL-6 levels. Regarding gestational age, IL-6 levels are higher in preterm infants compared to full-term newborns. The determination of IL-6 from umbilical cord blood has a sensitivity of over 87% for early-onset sepsis [105,106]. Serological tests have a sensitivity that ranges from 75% to 85%. The cutoff levels for these tests are set at 80 pg/ml for the first day of life, 40 pg/ml for days 2 to 7, and 30 pg/ml after the first week. The specificity of these tests is relatively good, ranging from 72.8% to 88% [107]. Additionally, interleukin-6 (IL-6) plays a significant role in increasing vasodilatory prostaglandins, which can contribute to PDA [105].

3.3.2. Interleukin-8 (IL-8)

Interleukin-8 (IL-8) is a pro-inflammatory cytokine primarily produced by monocytes, essential for host defense against infectious diseases. It regulates inflammatory and immune responses and serves as an essential chemotactic factor, facilitating neutrophil recruitment and activation [108]. IL-8 can be used as an early marker for early diagnosis of neonatal sepsis [109,110]. A level of 60 pg/mL was the upper limit for IL-8 in non-infected neonates, while a level of 142.4 ± 111.6 pg/mL was found in newborns with early-onset sepsis [111]. This cytokine is linked to the persistence of PDA and the evaluation of response to ductus arteriosus closure [104,112].

3.3.3. Interleukin-10 (IL-10)

Interleukin-10 (IL-10) is a cytokine involved in maintaining systemic homeostasis and modulating inflammation. IL-10 is produced by various lymphoid, myeloid, and mast cells and belongs to the IL-10 cytokine family, which also includes IL-19, IL-20, IL-22, IL-24, IL-26, and interferons. The ability of interleukin-10 (IL-10) to suppress pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 makes it a promising therapeutic target for treating inflammatory disorders [113].
A study by Sellmer et al. revealed that newborns with a hsPDA exhibited elevated levels of interleukin-6, interleukin-8, and interleukin-10. In contrast, complement component 8 and carboxypeptidase levels were decreased compared to newborns without persistent fetal circulation [82].

3.3.4. Growth Differentiation Factor 15 (GDF-15)

Growth Differentiation Factor 15 (GDF-15) is associated with inflammatory processes and acts as a stress-responsive cytokine. Higher levels of GDF-15 are associated with an increased risk of chronic kidney disease, cardiovascular diseases, and pulmonary conditions like pulmonary hypertension and pulmonary fibrosis [114].
During pregnancy, the placenta releases increased amounts of GDF-15, leading to higher levels of this protein in maternal serum. Almudarez et al. discovered that GDF-15 levels decreased with gestational age, while elevated levels were linked to respiratory issues, more extended hospital stays, and increased ventilator support [115]. GDF-15 could be a valuable biomarker for monitoring children with congenital heart disease and congestive heart failure, helping assess disease severity and guide treatment [116].

3.3.5. Monocyte Chemoattractant Protein-1 (MCP-1/CCL2)

Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a cytokine from the chemokine family that acts as a strong attractant for monocytes by activating G protein-coupled receptors. It plays a key role in the migration and infiltration of monocytes and macrophages. This migration across the vascular endothelium is typically a physiologic process for monitoring tissues, but it can also occur in response to inflammation during pathological conditions. Experimental evidence indicates that CCL2 deficiency is linked to a significant decrease in arterial lipid deposits, while elevated levels of CCL2 are associated with atherosclerosis [117,118].

3.3.6. Macrophage Inflammatory Protein-1α (MIP-1α/CCL3)

Macrophage Inflammatory Protein-1α (MIP-1α/CCL3) is a member of the chemokine family. It can be secreted by various immune cells, including monocytes, T lymphocytes, B lymphocytes, neutrophils, dendritic cells, and natural killer (NK) cells, alongside MIP-1β/CCL4. MIP-1α/CCL3 plays several roles, including recruiting inflammatory cells, inhibiting stem cell functions, and supporting the immune response. Typically, the measured levels of this chemokine are low. Cells that secrete MIP-1α/CCL3 are found in areas experiencing accelerated inflammation or in regions where bone resorption occurs. Patients diagnosed with conditions such as Sjögren’s syndrome, multiple myeloma, or rheumatoid arthritis often exhibit elevated levels of MIP-1α/CCL3. Additionally, patients who have suffered a myocardial infarction or have conditions leading to congestive heart failure also show increased levels of this chemokine [119].
Yu-Jen Wei et al. investigated the association between intrauterine inflammation and PDA in preterm infants. They assessed the fetal inflammatory response by measuring interleukin 6 (IL-6) levels in the umbilical cord. A level above 11 pg/mL suggests a strong inflammatory response, increasing the risk of intraventricular hemorrhage, chronic lung disease, and cerebral palsy [104]. A study conducted by Olsson indicates that elevated levels of Interleukin-6 (IL-6), IL-8, IL-10, IL-12, growth/differentiation factor 15 (GDF-15), monocyte chemoattractant protein-1 (MCP-1/CCL2), and macrophage inflammatory protein-1α (MIP-1α/CCL3) are associated with PDA [112]. Aikio et al. studied the impact of paracetamol on serum inflammatory biomarkers in very preterm infants with respiratory distress. During the early treatment (<60 h), Paracetamol had no effect on cytokine levels, but later treatment (60–120 h) was associated with lower IL-10 and MIP-1α/CCL3. It is unclear whether the decrease in cytokines results from reduced circulatory stress due to PDA constriction caused by treatment or if it reflects a direct systemic anti-inflammatory effect [120].

Limitation of This Review

This article provides a general overview of the available literature on serum biomarkers and PDA in preterm infants. The literature is considerable and varied, making a structured methodological search challenging.

4. Conclusions

Echocardiographic and serum biochemical markers alone cannot reliably determine whether a PDA is hemodynamically significant. Clinical judgment must integrate these evaluations, particularly when deciding to treat a PDA. This thoughtful approach can guide appropriate interventions and help avoid unnecessary treatments, ensuring optimal patient care. The use of biomarkers in diagnosing and managing PDA is an underexplored opportunity, even though it is not routinely practiced. Biomarkers, including B-type natriuretic peptides and clinical signs, could serve as valuable diagnostic tools when echocardiography or point-of-care ultrasound are unavailable. The routine implementation of biomarkers in clinical practice requires further validation through more studies and improved diagnostic accessibility.
Research revealed a strong correlation between NT-proBNP and MR-proANP levels and echocardiographic parameters in patients with significant patent ductus arteriosus, suggesting that serial measurements may be valuable for assessing clinical outcomes and responses to medical treatment. Future research should focus on investigating new biomarkers associated with the underlying mechanisms of perinatal ductus arteriosus dynamics in preterm infants.

Author Contributions

Conceptualization, M.C., and E.M.; methodology, M.C., M.S., R.M., and M.A.-C; software, M.A.-C., A.R.; validation, M.C., E.M., R.M., and Z.S.-S; formal analysis, M.C., E.M., R.M., and M.S.; investigation, M.C., R.M., M.S., M.A.-C., A.R., Z.S.-S., M.-G.F., A.T., E.M., and V.M.; resources, M.C., R.M., M.S., and E.M.; data curation, M.C., R.M., M.S., M.-G.F., Z.S.-S., and V.M.; writing—original draft preparation, M.C., and E.M.; writing—review and editing, M.C., R.M., M.S., and E.M.; visualization, M.C., R.M., M.S., M.A.-C., A.R., Z.S.-S., M.-G.F., A.T., E.M., and V.M.; supervision, M.C., and E.M.; project administration, M.C., and E.M.; funding acquisition, M.C. All authors have read and agreed to the published version of the manuscript

Funding

This research was funded by the University of Medicine, Pharmacy, Sciences and Technology George Emil Palade of Targu Mures, grant number 10126/3, 17 December 2020.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the
corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kikuchi N, Goto T, Katsumata N, Murakami Y, Shinohara T, Maebayashi Y, Sakakibara A, Saito C, Hasebe Y, Hoshiai M, Nemoto A, Naito A. Correlation between the Closure Time of Patent Ductus Arteriosus in Preterm Infants and Long-Term Neurodevelopmental Outcome. J Cardiovasc Dev Dis. 2024 Jan 16;11(1):26. [CrossRef]
  2. Alvarez SGV, McBrien A. Ductus arteriosus and fetal echocardiography: Implications for practice. Semin Fetal Neonatal Med. 2018 Aug;23(4):285-291. [CrossRef]
  3. Gournay, V. The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis. 2011 Nov;104(11):578-85. [CrossRef]
  4. Pugnaloni F, Doni D, Lucente M, Fiocchi S, Capolupo I. Ductus Arteriosus in Fetal and Perinatal Life. J Cardiovasc Dev Dis. 2024 Apr 1;11(4):113. [CrossRef]
  5. Hundscheid T, van den Broek M, van der Lee R, de Boode WP. Understanding the pathobiology in patent ductus arteriosus in prematurity-beyond prostaglandins and oxygen. Pediatr Res. 2019 Jul;86(1):28-38. [CrossRef]
  6. Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of Cardiac Natriuretic Peptides in Heart Structure and Function. Int J Mol Sci. 2022 Nov 20;23(22):14415. [CrossRef]
  7. Crockett SL, Berger CD, Shelton EL, Reese J. Molecular and mechanical factors contributing to ductus arteriosus patency and closure. Congenit Heart Dis. 2019 Jan;14(1):15-20. [CrossRef]
  8. Ovalı, F. Molecular and Mechanical Mechanisms Regulating Ductus Arteriosus Closure in Preterm Infants. Front Pediatr. 2020 Aug 25;8:516. [CrossRef]
  9. Thébaud B, Wu XC, Kajimoto H, Bonnet S, Hashimoto K, Michelakis ED, Archer SL. Developmental absence of the O2 sensitivity of L-type calcium channels in preterm ductus arteriosus smooth muscle cells impairs O2 constriction contributing to patent ductus arteriosus. Pediatr Res. 2008 Feb;63(2):176-81. [CrossRef]
  10. Hung YC, Yeh JL, Hsu JH. Molecular Mechanisms for Regulating Postnatal Ductus Arteriosus Closure. Int J Mol Sci. 2018 Jun 25;19(7):1861. [CrossRef]
  11. Chatziantoniou A, Rorris F-P, Samanidis G, Kanakis M. Keeping the Ductus Arteriosus Patent: Current Strategy and Perspectives. Diagnostics. 2025; 15(3):241. [CrossRef]
  12. Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, Hansmann G. Patent Ductus Arteriosus of the Preterm Infant. Pediatrics. 2020 Nov;146(5):e20201209. [CrossRef]
  13. Singh Y, Lakshminrusimha S. Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn. Clin Perinatol. 2021 Aug;48(3):595-618. [CrossRef]
  14. Bakas AM, Healy HM, Bell KA, Brown DW, Mullen M, Scheid A. Prenatal duct closure leading to severe pulmonary hypertension in a preterm neonate-a case report. Cardiovasc Diagn Ther. 2020 Oct;10(5):1691-1695. [CrossRef]
  15. Operle M, Anderson S. Premature Closure of the Ductus Arteriosus in an Otherwise Healthy Fetus. Journal of Diagnostic Medical Sonography. 2019;35(3):235-239. [CrossRef]
  16. Zielinsky P, Piccoli AL Jr, Manica JL, Nicoloso LH. New insights on fetal ductal constriction: role of maternal ingestion of polyphenol-rich foods. Expert Rev Cardiovasc Ther. 2010 Feb;8(2):291-8. [CrossRef]
  17. Sung SI, Chang YS, Kim J, Choi JH, Ahn SY, Park WS. Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23-28 weeks of gestation. PLoS One. 2019 Feb 13;14(2):e0212256. [CrossRef]
  18. Chesi, E.; Rossi, K.; Ancora, G.; Baraldi, C.; Corradi, M.; Galletti, S.; Mescoli, G.; Papa, I.; Solinas, A.; Braglia, L.; Miselli, F.; Berardi, A.; Gargano, G. (2024). Patent ductus arteriosus (also non-hemodynamically significant) correlates with poor outcomes in very low birth weight infants. A multicenter cohort study. PLoS One 2024, 19, e0306769. [Google Scholar] [CrossRef] [PubMed]
  19. Cucerea M, Moscalu M, Ognean ML, Fagarasan A, Toma D, Marian R, Anciuc-Crauciuc M, Racean A, Gall Z, Simon M. Impact of Early Surfactant Administration on Ductus Arteriosus Assessed at 24 h in Preterm Neonates Less than 32 Weeks of Gestational Age. Biomedicines. 2024 ;12(6):1136. [CrossRef]
  20. Kotidis C, Wertheim D, Weindling M, Rabe H, Turner MA. Assessing patent ductus arteriosus in preterm infants from standard neonatal intensive care monitoring. Eur J Pediatr. 2022 Mar;181(3):1117-1124. [CrossRef] [PubMed]
  21. Singh Y, Fraisse A, Erdeve O, Atasay B. Echocardiographic Diagnosis and Hemodynamic Evaluation of Patent Ductus Arteriosus in Extremely Low Gestational Age Newborn (ELGAN) Infants. Front Pediatr. 2020 Nov 19;8:573627. [CrossRef]
  22. Surak A, Sidhu A, Ting JY. Should we “eliminate” PDA shunt in preterm infants? A narrative review. Front Pediatr. 2024 Feb 6;12:1257694. [CrossRef]
  23. Rubattu S, Volpe M. Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. Int J Mol Sci. 2019 Aug 16;20(16):3991. [CrossRef]
  24. Rao S, Pena C, Shurmur S, Nugent K. Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review. Curr Cardiol Rev. 2021;17(6):e051121191003. [CrossRef]
  25. Weil J, Bidlingmaier F, Döhlemann C, Kuhnle U, Strom T, Lang RE. Comparison of plasma atrial natriuretic peptide levels in healthy children from birth to adolescence and in children with cardiac diseases. Pediatr Res. 1986 Dec;20(12):1328-31. [CrossRef]
  26. Weir FJ, Smith A, Littleton P, Carter N, Hamilton PA. Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. Acta Paediatr. 1992 Sep;81(9):672-5. [CrossRef]
  27. Xie H, Huo Y, Chen Q, Hou X. Application of B-Type Natriuretic Peptide in Neonatal Diseases. Front Pediatr. 2021 Dec 7;9:767173. [CrossRef] [PubMed]
  28. Fritz AS, Keller T, Kribs A, Hünseler C. Reference values for N-terminal Pro-brain natriuretic peptide in premature infants during their first weeks of life. Eur J Pediatr. 2021 Apr;180(4):1193-1201. [CrossRef]
  29. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006 Jun;92(6):843-9. [CrossRef] [PubMed]
  30. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart. 2003 Aug;89(8):875-8. [CrossRef]
  31. Cantinotti M, Storti S, Parri MS, Murzi M, Clerico A. Reference values for plasma B-type natriuretic peptide in the first days of life. Clin Chem. 2009 Jul;55(7):1438-40. [CrossRef] [PubMed]
  32. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003 Jul 26;362(9380):316-22. [CrossRef]
  33. Kara K, Lehmann N, Neumann T, Kälsch H, Möhlenkamp S, Dykun I, Broecker-Preuss M, Pundt N, Moebus S, Jöckel KH, Erbel R, Mahabadi AA. NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study. Int J Cardiol. 2015 Mar 15;183:155-61. [CrossRef]
  34. Dasgupta S, Aly AM, Malloy MH, Okorodudu AO, Jain SK. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol. 2018 Sep;38(9):1252-1257. [CrossRef]
  35. Fritz AS, Keller T, Kribs A, Hünseler C. Diseases associated with prematurity in correlation with N-terminal pro-brain natriuretic peptide levels during the early postnatal life. Eur J Pediatr. 2023 Jul;182(7):3075-3082. [CrossRef]
  36. Schroeder L, Ebach F, Melaku T, Strizek B, Jimenez-Cruz J, Dolscheid-Pommerich R, Mueller A, Kipfmueller F. Longitudinal evaluation of hemodynamic blood and echocardiographic biomarkers for the prediction of BPD and BPD-related pulmonary hypertension in very-low-birth-weight preterm infants. Eur J Pediatr. 2024 Nov 15;184(1):15. [CrossRef] [PubMed]
  37. Neumann RP, Gerull R, Hasler PW, Wellmann S, Schulzke SM. Vasoactive peptides as biomarkers for the prediction of retinopathy of prematurity. Pediatr Res. 2024 Jun;95(7):1868-1874. [CrossRef]
  38. Tan W, Li B, Wang Z, Zou J, Jia Y, Yoshida S, Zhou Y. Novel Potential Biomarkers for Retinopathy of Prematurity. Front Med (Lausanne). 2022 Feb 2;9:840030. [CrossRef]
  39. Yang C, Ma J, Guo L, Li B, Wang L, Li M, Wang T, Xu P, Zhao C. NT-Pro-BNP and echocardiography for the early assessment of cardiovascular dysfunction in neonates with sepsis. Medicine (Baltimore). 2022 Sep 16;101(37):e30439. [CrossRef]
  40. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M. B-type natriuretic peptide to predict ductus intervention in infants . [CrossRef]
  41. Cui Q, Liu X, Su G, Zhou C, Wang J. Change and clinical significance of serum cortisol, BNP, and PGE-2 levels in premature infants with patent ductus arteriosus. Transl Pediatr. 2021 Oct;10(10):2573-2578. [CrossRef]
  42. König K, Guy KJ, Drew SM, Barfield CP. B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants. Acta Paediatr. 2015 Apr;104(4):e139-42. [CrossRef]
  43. Parra-Bravo JR, Valdovinos-Ponce MT, García H, Núñez-Enríquez JC, Jiménez-Cárdenas ML, Avilés-Monjaraz R, Lavana-Hernández W. B-type brain natriuretic peptide as marker of hemodynamic overload of the patent ductus arteriosus in the preterm infant]. Arch Cardiol Mex. 2020 Nov 3;91(1):17-24. Spanish. [CrossRef]
  44. Kim JS, Shim EJ. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J. 2012 Mar;42(3):192-6. [CrossRef]
  45. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics. 2005 Mar;115(3):e255-61. [CrossRef]
  46. Mine K, Ohashi A, Tsuji S, Nakashima J, Hirabayashi M, Kaneko K. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Acta Paediatr. 2013 Aug;102(8):e347-52. [CrossRef]
  47. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L’Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol. 2005 Nov;25(11):709-13. [CrossRef]
  48. Kalra, V.K.; DeBari, V.A.; Zauk, A.; Kataria, P.; Myridakis, D.; Kiblawi, F. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci. 2011, 41, 131–137. [Google Scholar] [PubMed]
  49. Zekri HS, Said RN, Hegazy RA, Darwish RK, Kamel A, Abd El Hakim NG. B-type Natriuretic Peptide: A Diagnostic Biomarker for a Hemodynamically Significant PDA. Open Access Macedonian Journal of Medical Sciences. 22; 10(B):877-883. [CrossRef]
  50. Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants? Neonatology. 2013;103(2):118-22. [CrossRef]
  51. Shin J, Lee EH, Lee JH, Choi BM, Hong YS. Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants. Korean J Pediatr. 2017 Jun;60(6):175-180. [CrossRef]
  52. Liu, Y.; Huang, Z.-L.; Gong, L.; Zhang, Z.; Zhang, S.-C.; Zhou, Y.-X. N-terminal pro-brain natriuretic peptide used for screening hemodynamically significant patent ductus arteriosus in very low birth weight infants: How and when? Clinical Hemorheology and Microcirculation 2020, 75, 335–347. [Google Scholar] [CrossRef] [PubMed]
  53. Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol. 2009 Feb;29(2):137-42. [CrossRef]
  54. Harris SL, More K, Dixon B, Troughton R, Pemberton C, Horwood J, Ellis N, Austin N. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr. 2018 Apr;177(4):521-532. [CrossRef]
  55. Gudmundsdottir A, Bartocci M, Picard O, Ekström J, Chakhunashvili A, Bohlin K, Attner C, Printz G, Karlsson M, Mohlkert LA, Karlén J, Pegelow Halvorsen C, Edstedt Bonamy AK. Early N-Terminal Pro B-Type Natriuretic Peptide (NTproBNP) Plasma Values and Associations with Patent Ductus Arteriosus Closure and Treatment-An Echocardiography Study of Extremely Preterm Infants. J Clin Med. 2022 Jan 27;11(3):667. [CrossRef]
  56. Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr. 2009 Aug;98(8):1254-9. [CrossRef]
  57. Asrani P, Aly AM, Jiwani AK, Niebuhr BR, Christenson RH, Jain SK. High-sensitivity troponin T in preterm infants with a hemodynamically significant patent ductus arteriosus. J Perinatol. 2018 Nov;38(11):1483-1489. [CrossRef]
  58. Rodriguez-Blanco S, Oulego-Erroz I, Gautreaux-Minaya S, Perez-Muñuzuri A, Couce-Pico ML. Early NT-proBNP levels as a screening tool for the detection of hemodynamically significant patent ductus arteriosus during the first week of life in very low birth weight infants. J Perinatol. 2018 Jul;38(7):881-888. [CrossRef]
  59. Buddhe S, Dhuper S, Kim R, Weichbrod L, Mahdi E, Shah N, Kona S, Sokal M. NT-proBNP Levels Improve the Ability of Predicting a Hemodynamically Significant Patent Ductus Arteriosus in Very Low-Birth-Weight Infants. J Clin Neonatol. 2012 Apr;1(2):82-6. [CrossRef]
  60. Lin Y-L, Hung Y-L, Shen C-M, Chen Y-C, Hsieh W-S. Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants? Children. 2022; 9(7):1002. [CrossRef]
  61. Gokulakrishnan G, Kulkarni M, He S, Leeflang MM, Cabrera AG, Fernandes CJ, Pammi M. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates. Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. [CrossRef]
  62. Köstekci YE, Erdeve Ö. Patent ductus arteriosus (PDA): Recent recommendations for to close or not to close. Global Pediatrics 23 7(5):100128. doi.org/10.1016/j.gpeds.2023.100128. 20 December.
  63. Tarkowska A, Furmaga-Jabłońska W. The Evaluation of Cardiac Troponin T in Newborns. Biomed Hub. 2017 Oct 10;2(3):1-7. [CrossRef]
  64. Karlén J, Karlsson M, Eliasson H, Bonamy AE, Halvorsen CP. Cardiac Troponin T in Healthy Full-Term Infants. Pediatr Cardiol. 2019 Dec;40(8):1645-1654. [CrossRef]
  65. Osredkar J, Bajrić A, Možina H, Lipar L, Jerin A. Cardiac Troponins I and T as Biomarkers of Cardiomyocyte Injury—Advantages and Disadvantages of Each. Applied Sciences. 2024; 14(14):6007. [CrossRef]
  66. Kontos MC, Turlington JS. High-Sensitivity Troponins in Cardiovascular Disease. Curr Cardiol Rep. 2020 Mar 30;22(5):30. [CrossRef]
  67. Trevisanuto D, Pitton M, Altinier S, Zaninotto M, Plebani M, Zanardo V. Cardiac troponin I, cardiac troponin T and creatine kinase MB concentrations in umbilical cord blood of healthy term neonates. Acta Paediatr. 2003;92:1463–1467. [CrossRef]
  68. Clark SJ, Newland P, Yoxall CW, Subhedar NV. Concentrations of cardiac troponin T in neonates with and without respiratory distress. Arch Dis Child Fetal Neonatal Ed. 2004;89:F348–F352. [CrossRef]
  69. Yildirim A, Ozgen F, Ucar B, Alatas O, Tekin N, Kilic Z. The diagnostic value of troponin T level in the determination of cardiac damage in perinatal asphyxia newborns. Fetal Pediatr Pathol. 2016;35:29–36. [CrossRef]
  70. Jones R, Heep A, Odd D. Biochemical and clinical predictors of hypoxic-ischemic encephalopathy after perinatal asphyxia. J Matern Fetal Neonatal Med. 2018;31:791–796. [CrossRef]
  71. El-Khuffash AF, Molloy EJ. Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants. J Pediatr. 2008;153:350–353. [CrossRef]
  72. Mohamed MH, Aboraya HM, Makawy MA, Elgebaly HH. Cardiac Troponin T in very low birthweight preterm infants with patent ductus arteriosus, QJM: An International Journal of Medicine, Volume 113, Issue Supplement_1, March 2020, hcaa063.037. [CrossRef]
  73. Omar HR, Abed NT, El-Falah AA, Elsayes, ME. High-sensitivity troponin T in preterm infants with a hemodynamically significant patent ductus arteriosus. International Journal of Health Sciences. 2022; 6(S6), 8220–8230. [CrossRef]
  74. Vaisbourd Y, Sharif D, Riskin A, Yaniv L, Dinur G, Amen K, Bader D, Kugelman A. The effect of patent ductus arteriosus on coronary artery blood flow in premature infants: a prospective observational pilot study. J Perinatol. 2020 Sep;40(9):1366-1374. [CrossRef]
  75. Veysizadeh M, Khodadadi M, Zarkesh MR, Kamrani K, Kaveh M, Shariat M. Finding a biomarker to predict patent ductus arteriosus in preterm babies. World Journal of Advanced Research and Reviews. 22;16(1):259-265. [CrossRef]
  76. Koyama T, Kuriyama N, Suzuki Y, Saito S, Tanaka R, Iwao M, Tanaka M, Maki T, Itoh H, Ihara M, Shindo T, Uehara R. Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study. Sci Rep. 2021 Jan 11;11(1):305. Erratum in: Sci Rep. 2021 Aug 30;11(1):17638. 10.1038/s41598-021-96984-3. [CrossRef]
  77. Krintus M, Kozinski M, Braga F, Kubica J, Sypniewska G, Panteghini M. Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clin Chem Lab Med. 2018 Jun 27;56(7):1161-1168. [CrossRef]
  78. Valenzuela-Sánchez F, Valenzuela-Méndez B, Rodríguez-Gutiérrez JF, Estella-García Á, González-García MÁ. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. Ann Transl Med. 2016 Sep;4(17):329. [CrossRef]
  79. Oncel MY, Dilmen U, Erdeve O, Ozdemir R, Calisici E, Yurttutan S, Canpolat FE, Oguz SS, Uras N. Proadrenomedullin as a prognostic marker in neonatal sepsis. Pediatr Res. 2012 Nov;72(5):507-12. [CrossRef]
  80. Fahmey SS, Mostafa H, Elhafeez NA, Hussain H. Diagnostic and prognostic value of proadrenomedullin in neonatal sepsis. Korean J Pediatr. 2018 May;61(5):156-159. [CrossRef]
  81. Admaty D, Benzing J, Burkhardt T, Lapaire O, Hegi L, Szinnai G, Morgenthaler NG, Bucher HU, Bührer C, Wellmann S. Plasma midregional proadrenomedullin in newborn infants: impact of prematurity and perinatal infection. Pediatr Res. 2012 Jul;72(1):70-6. [CrossRef]
  82. Wu, R.Z.; Rong, X.; Ren, Y.; He, X.X.; Xiang, R.L. [Heart rate variability, adrenomedullin and B-type natriuretic peptide before and after transcatheter closure in children with patent ductus arteriosus]. Zhonghua Xin Xue Guan Bing Za Zhi 2010, 38, 334–336. [Google Scholar] [PubMed]
  83. Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):41-52. [CrossRef]
  84. Buendgens L, Yagmur E, Bruensing J, Herbers U, Baeck C, Trautwein C, Koch A, Tacke F. C-terminal proendothelin-1 (CT-proET-1) is associated with organ failure and predicts mortality in critically ill patients. J Intensive Care. 2017 Mar 20;5:25. [CrossRef]
  85. Houde M, Desbiens L, D’Orléans-Juste P. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. Adv Pharmacol. 2016;77:143-75. [CrossRef]
  86. Niu JO, Munshi UK, Siddiq MM, Parton LA. Early increase in endothelin-1 in tracheal aspirates of preterm infants: correlation with bronchopulmonary dysplasia. J Pediatr. 1998 Jun;132(6):965-70. [CrossRef]
  87. Baumann P, et al. Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia. Neonatology. 2015;108:293–296. [CrossRef]
  88. Gerull R, Neumann RP, Atkinson A, Bernasconi L, Schulzke SM, Wellmann S. Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1). Pediatr Res. 2022 May;91(6):1478-1484. [CrossRef]
  89. Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG, Bucher HU, Buhrer C, Arlettaz R, Wellmann S (2012) Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus. Neonatology 101 (2):116-124. [CrossRef]
  90. Grass B, Baumann P, Arlettaz R, Fouzas S, Meyer P, Spanaus K, Wellmann S. Cardiovascular biomarkers pro-atrial natriuretic peptide and pro-endothelin-1 to monitor ductus arteriosus evolution in very preterm infants. Early Hum Dev. 2014 Jun;90(6):293-8. [CrossRef] [PubMed]
  91. Sellmer A, Hjortdal VE, Bjerre JV, Schmidt MR, Bech BH, Henriksen TB. Cardiovascular biomarkers in the evaluation of patent ductus arteriosus in very preterm neonates: A cohort study. Early Hum Dev. 2020 Oct;149:105142. [CrossRef] [PubMed]
  92. Yoshimura M, Conway-Campbell B, Ueta Y. Arginine vasopressin: Direct and indirect action on metabolism. Peptides. 2021 Aug;142:170555. [CrossRef] [PubMed] [PubMed Central]
  93. Evers KS, Wellmann S. Arginine Vasopressin and Copeptin in Perinatology. Front Pediatr. 2016 Aug 2;4:75. [CrossRef]
  94. Jalleh R, Torpy DJ. The Emerging Role of Copeptin. Clin Biochem Rev. 2021 Feb;42(1):17-25. [CrossRef]
  95. Benzing J, Wellmann S, Achini F, Letzner J, Burkhardt T, Beinder E, Morgenthaler NG, Haagen U, Bucher HU, Bührer C, Lapaire O, Szinnai G. Plasma copeptin in preterm infants: a highly sensitive marker of fetal and neonatal stress. J Clin Endocrinol Metab. 2011 Jun;96(6):E982-5. [CrossRef]
  96. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson Roberts L 2nd, Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol. 2007;433:113-26. [CrossRef]
  97. Dani C, Pratesi S. Patent ductus arteriosus and oxidative stress in preterm infants: a narrative review. Transl Pediatr. 2020 Dec;9(6):835-839. [CrossRef]
  98. Comporti M, Signorini C, Leoncini S, Buonocore G, Rossi V, Ciccoli L. Plasma F2-isoprostanes are elevated in newborns and inversely correlated to gestational age. Free Radic Biol Med. 2004 Sep 1;37(5):724-32. [CrossRef]
  99. Coviello C, Perrone S, Buonocore G, Negro S, Longini M, Dani C, de Vries LS, Groenendaal F, Vijlbrief DC, Benders MJNL, Tataranno ML. Isoprostanes as Biomarker for White Matter Injury in Extremely Preterm Infants. Front Pediatr. 2021 Jan 15;8:618622. [CrossRef]
  100. Lembo C, Buonocore G, Perrone S. Oxidative Stress in Preterm Newborns. Antioxidants. 2021; 10(11):1672. [CrossRef]
  101. Chen JX, O’Mara PW, Poole SD, Brown N, Ehinger NJ, Slaughter JC, Paria BC, Aschner JL, Reese J. Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus. Pediatr Res. 2012 Aug;72(2):122-8. [CrossRef]
  102. Inayat M, Bany-Mohammed F, Valencia A, Tay C, Jacinto J, Aranda JV, Beharry KD. Antioxidants and Biomarkers of Oxidative Stress in Preterm Infants with Symptomatic Patent Ductus Arteriosus. Am J Perinatol. 2015 Jul;32(9):895-904. [CrossRef]
  103. Coviello C, Tataranno ML, Corsini I, Leonardi V, Longini M, Bazzini F, Buonocore G, Dani C. Isoprostanes as Biomarker for Patent Ductus Arteriosus in Preterm Infants. Front Pediatr. 2020 Sep 8;8:555. [CrossRef]
  104. Wei YJ, Hsu R, Lin YC, Wong TW, Kan CD, Wang JN. The Association of Patent Ductus Arteriosus with Inflammation: A Narrative Review of the Role of Inflammatory Biomarkers and Treatment Strategy in Premature Infants. Int J Mol Sci. 2022 Nov 10;23(22):13877. [CrossRef]
  105. Cakir U, Tayman C. Systemic Inflammatory Indices as New Biomarkers for Hemodynamically Significant Ductus Arteriosus. Arq Bras Cardiol. 2024 Nov;121(11):e20240211. Portuguese, English. [CrossRef]
  106. Eichberger J, Resch B. Reliability of Interleukin-6 Alone and in Combination for Diagnosis of Early Onset Neonatal Sepsis: Systematic Review. Front Pediatr. 2022 Mar 23;10:840778. [CrossRef]
  107. Küng E, Unterasinger L, Waldhör T, Berger A, Wisgrill L. Cut-off values of serum interleukin-6 for culture-confirmed sepsis in neonates. Pediatr Res. 2023 Jun;93(7):1969-1974. [CrossRef]
  108. Gude SS, Peddi NC, Vuppalapati S, Venu Gopal S, Marasandra Ramesh H, Gude SS. Biomarkers of Neonatal Sepsis: From Being Mere Numbers to Becoming Guiding Diagnostics. Cureus. 2022 Mar 16;14(3):e23215. [CrossRef]
  109. Zhou M, Cheng S, Yu J, Lu Q. Interleukin-8 for diagnosis of neonatal sepsis: a meta-analysis. PLoS One. 2015 ;10(5):e0127170. [CrossRef]
  110. Dembinski J, Behrendt D, Heep A, Dorn C, Reinsberg J, Bartmann P. Cell-associated interleukin-8 in cord blood of term and preterm infants. Clin Diagn Lab Immunol. 2002 Mar;9(2):320-3. [CrossRef]
  111. Orlikowsky TW, Neunhoeffer F, Goelz R, Eichner M, Henkel C, Zwirner M, Poets CF. Evaluation of IL-8-concentrations in plasma and lysed EDTA-blood in healthy neonates and those with suspected early onset bacterial infection. Pediatr Res. 2004 Nov;56(5):804-9. [CrossRef]
  112. Olsson KW, Larsson A, Jonzon A, Sindelar R. Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks’ gestation. Pediatr Res. 2019 Sep;86(3):333-338. [CrossRef]
  113. Minshawi F, Lanvermann S, McKenzie E, Jeffery R, Couper K, Papoutsopoulou S, Roers A, Muller W. The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function. Front Immunol. 2020 Aug 11;11:1794. [CrossRef]
  114. Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017 Jan;63(1):140-151. [CrossRef]
  115. Almudares F, Hagan J, Chen X, Devaraj S, Moorthy B, Lingappan K. Growth and differentiation factor 15 (GDF15) levels predict adverse respiratory outcomes in premature neonates. Pediatr Pulmonol. 2023 Jan;58(1):271-278. [CrossRef]
  116. Paneitz DC, Zhou A, Yanek L, Golla S, Avula S, Kannankeril PJ, Everett AD, Mettler BA, Gottlieb Sen D. Growth Differentiation Factor 15: A Novel Growth Biomarker for Children With Congenital Heart Disease. World J Pediatr Congenit Heart Surg. 2022 Nov;13(6):745-751. [CrossRef]
  117. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009 Jun;29(6):313-26. [CrossRef]
  118. Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009 Mar;11(2):131-8. [CrossRef]
  119. Bhavsar I, Miller CS, Al-Sabbagh M. Macrophage Inflammatory Protein-1 Alpha (MIP-1 alpha)/CCL3: As a Biomarker. General Methods in Biomarker Research and their Applications. 2015 Jun 1:223–49. [CrossRef]
  120. Aikio O, Härmä A, Härkin P, Leskinen M, Valkama M, Saarela T, Salminen A, Hallman M. Inflammatory biomarkers in very preterm infants during early intravenous paracetamol administration. Early Hum Dev. 2021 Oct;161:105464. [CrossRef]
Table 1. Summary of associations between plasma BNP levels and PDA in preterm infants.
Table 1. Summary of associations between plasma BNP levels and PDA in preterm infants.
GA weeks n Age
days 		BNP (pg/mL)
PDA No PDA Cutoff value Sensitivity Specificity Study Findings
Czernik [40] <28
Median 26		 67 1-2 1069 (564–1845)
87 (17–130) #		 247 (121–463) 550 83% 86% BNP is correlated with DA size (R = 0.46, p < 0.001)
Cui Q [41] 28–32 67 3 95.20±7.42 70.15±6.44 - 68.9% 69% BNP is correlated with early diagnosis and progression of PDA
König [42] <32 58 1-4 486.5 (219–1316) 190 (95.5–514.5) - - - BNP is correlated with PDA size (R = 0.35, p = 0.0066)
Parra-Bravo [43] < 32 29 3-5 1061.9 ± 105.7 219.9 ± 227.8 486.5 81% 92% BNP is correlated with hsPDA
(R = 0.71; p < 0.001)
Kim [44] <37
32.7 (28.4-35.8)		 28 4 654.68 (428.29-1280) 124.52 (37.21-290.49) 412 100% 95% BNP is correlated with hsPDA
Choi [45] 25-34 66 3 2896 ± 1627 208 ± 313 1110 100% 95.3% BNP is correlated with the magnitude of the DA shunt
Mine [46] <33 46 2-3 283.4 (123.1–226.2) 88.4 (38.6–191.4) 250
2000 		80% 40% BNP is predictive for PDA treatment (indomethacin)
BNP is predictive for PDA surgery
Sanjeev [47] ≤34 29 2-28 508.5±618.2 59.5±69.9 70 92.9% 73.3% BNP is correlated with hsPDA
Kalra [48] <34 52 3-7 2410 (420–2770) 23.6 (13.1–32.8) 123 100% 100% BNP is predictive for decision for treatment
Zekri [49] ≤35 73 1–2 536 (36–5665) 59.25 (11.5–331) 160.5 80.49% 90.62% BNP is correlated with PDA size
Lee [50] 27.1±2.2 73 1 921 (318–2133) 152 (91–450) >200
> 900		 83.9%
54.8%		 61.9%
95.2%		 BNP at 24 h is correlated
with the magnitude of the of the DA shunt
BNP at 24 h – guide for early targeted treatment of hsPDA
Data are presented as mean ± SD or median (range) due to lack of Gaussian distribution; GA—gestational age; n—number of cases; DA—ductus arteriosus; PDA—patent ductus arteriosus; BNP—brain natriuretic peptide; hsPDA— hemodynamically significant patent ductus arteriosus; # after intervention.
Table 2. Summary of associations between plasma NT-proBNP levels and PDA in preterm infants.
Table 2. Summary of associations between plasma NT-proBNP levels and PDA in preterm infants.
GA weeks n Age
days 		NT-proBNP (pg/mL)
PDA No PDA Cutoff value Sensitivity Specificity Study Findings
Liu Y [52] 30.6±1.5 120 1
2
3		 2050.0±590.5
5716.8±2267.0
5505.1±2210.2		 1865.4±436.6
2765.5±793.1
1618.7±782.3
3689
2331.5
83.7%
97.7%
93.5%
89.6%		 NTproBNP is predictive for hsPDA
NTproBNP is correlated with the magnitude of DA shunt
Day three of life
is the optimal testing time
Nuntnarumit [53] <37 35 2 16353 (10316-104998) 3914 (1535-19516) 10180 100% 91% NT-proBNP is predictive for HsPDA
Fritz [35] ≤ 31 118 1-7 7843 (2915–14116) 1896 (1277–5200) - - - NT-proBNP is correlated with the severity of PDA
König [42] <32 58 1-4 10858.5 (6319–42 108) 7488 (3363–14 227.5) - - - NT-proBNP is correlated with PDA size
Harris [54] < 30 51 3 1840 (1058) 178 (140) 287 92% 92% NT-proBNP is predictive for hsPDA
Gudmundsdottir [55] < 28 98 3 14600 (7740–28100)
32300 (29100–35000) *		 1810 (1760–6000) 6001–9000
15001–18000		 61%
66%		 20%
66%		 NT-proBNP is predictive for spontaneous DA closure
Predictive for PDA surgery
Ramakrishnan [56] 29 56 2 6952 1206 2850 90% 89% NT-proBNP is predictive for PDA treatment
Asrani [57] <34 70 1-5 18181.02 3149.23 3460 88% 72% NT-proBNP is an excellent diagnostic test for PDA
Rodriguez-Blanco [58] ≤32 85 2-3 33171 (5337–60684) 2065 (1093–4448) 5099 94% 82% NT-proBNP at 48–96 h of life can be used to exclude hsPDA
Buddhe [59] 27±2.6 69 3-5 24420±3190 3072±332 5900 96% 90% NT-proBNP helps timing of intervention of a hsPDA
Lin [60] 30.8 ± 3.3 36 2 9233.5 4262.5 - - - NT-proBNP might predict the effectiveness of the treatment.
Data are presented as mean ± SD or median (range) due to lack of Gaussian distribution; GA—gestational age; n—number of cases; PDA—patent ductus arteriosus; NT-proBNP—N-terminal pro-brain natriuretic peptide; hsPDA— hemodynamically significant patent ductus arteriosus. *Need for surgery.
Table 3. Summary of associations between plasma cTnT levels and PDA in preterm infants.
Table 3. Summary of associations between plasma cTnT levels and PDA in preterm infants.
GA weeks n Age
days 		cTnT(pg/mL)
PDA No PDA cutoff value Sensitivity Specificity Study Findings
Asrani [57] <34 70 2 251.5 ± 65.6 161 ± 22.4 170 70% 55% cTnT is a fair diagnostic test for PDA
EL-Khuffash [71] 28 (26.1-29.5) 80 ½-2 430 130 200 70% 75% cTnT significantly correlated with echocardiographic markers of DA significance
Mohamed [72] 31.7±61.57 77 2;5-7 310±60 160±30 - - - cTnT is correlated with PDA size
Omar [73] <34 60 1-4 182.7 ± 59.62 67.23 ± 25.96 >100 93.33% 90% cTnT can detect hsPDA
Vaisbourd [74] <32 43 1-3 hsPDA 200 ± 100
nhsPDA 120 ± 100		 100 ± 100 - - - cTnT is as sensitive as echocardiographic findings in hsPDA
Veysizadeh [75] 32.658±1.554 36 1-3 124.506±113.138 112.275±66.546 - - - There is no correlation between PDA and cTnT
Data are presented as mean ± SD or median (range) due to lack of Gaussian distribution; GA—gestational age; n—number of cases; PDA—patent ductus arteriosus; cTnT—Troponin; hsPDA— hemodynamically significant patent ductus arteriosus; nhsPDA—Nonsignificant PDA.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

76

Views

87

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated